<DOC>
	<DOCNO>NCT02658435</DOCNO>
	<brief_summary>The study aim provide evidence retinal safety support use tafenoquine potential single dose radical cure treatment patient Plasmodium vivax ( P. vivax ) malaria ( i.e. , co-administration schizonticidal drug TQ ) . The study conduct single mask , randomize , placebo-controlled , parallel group design . It assess retinal change baseline use spectral domain optical coherence tomography ( OCT ) fundus auto fluorescence ( FAF ) Month 3 ( 90 day ) post-dose adult healthy volunteer ( participant ) . A placebo control group use compare result TQ group . Interim analysis conduct complete 100 300 participant TQ group 50 150 participant match placebo .</brief_summary>
	<brief_title>Assessment Any Potential Retinal Effects Tafenoquine ( TQ )</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Tafenoquine</mesh_term>
	<criteria>Between 18 45 year age inclusive , time signing informed consent . Healthy determine investigator medically qualify designee base medical evaluation include medical history , brief physical examination , laboratory test . Participant value haematology chemistry within normal range . A participant clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =35 kilogram ( kg ) = &lt; 100kg Male OR Female . Female participant eligible participate pregnant ( confirm negative [ serum urine , accord site standard ] human chorionic gonadotrophin [ hCG ] test ) , lactate , least one follow condition applies : Nonreproductive potential define Premenopausal females one following : Documented tubal ligation Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion Hysterectomy Documented Bilateral Oophorectomy Postmenopausal define 12 month spontaneous amenorrhea questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) estradiol level consistent menopause ( refer site specific laboratory reference range confirmatory level ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . Reproductive potential agrees follow one option list Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) screen completion Day 90 followup visit . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Alanine Aminotransferase ( ALT ) bilirubin &gt; 1.5 time Upper Limit Normal ( ULN ) ( isolated bilirubin &gt; 1.5 time ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . The QT interval correct ( QTc ) heart rate accord Fridericia 's formula ( QTcF ) . QTcF &gt; 450 milli second ( msec ) . Other calculation method ( e.g . QT interval correct heart rate accord Bazett 's formula [ QTcB ] , individually correct QT interval [ QTcI ] ) machineread manually overread acceptable . Use prescription ( except female contraception acetaminophen dose = &lt; 2 gram ( g ) /day ) nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise participant safety . History regular alcohol consumption within 30 day study define : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 millilitre [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Positive result drug abuse Cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 30 day prior screen . History sensitivity TQ , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . History thalassaemia ; current past history methemoglobinemia methemoglobin percentage reference range screening . Lactating female . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 mL within 15 day dose TQ matchedplacebo . The participant participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day Participants hemoglobin value outside low limit normal range . A single repeat allow eligibility determination . Documented phenotypic Glucose6phosphate dehydrogenase ( G6PD ) deficiency , determine quantitative assay enzyme activity . Defined &lt; 70 % locally define median . A BCVA ( bilateral ) screen = &lt; 72 letter Eye disease could compromise assessment BCVA image posterior pole fundus photography , spectral domain OCT , FAF , likely require intervention 4 month ( approximately ) study participation ( e.g . cataract , glaucoma document visual field loss , ischemic optic neuropathy , retinitis pigmentosa ) History retinal vascular disease , retinal detachment , inflammatory disease , central serous chorioretinopathy , retinal disease may affect posterior retinal function architecture . Vitreoretinal interface disorder ( e.g . epiretinal membrane , vitreomacular traction ) may affect posterior retinal function architecture Intraocular surgery within 3 month dose Laser photocoagulation within 3 month dose High Myopia ( define equal , bad , 6.00 diopter ) Anterior , intermediate posterior uveitis ( active history ) history significant intraocular infectious disease ( e.g. , conjunctivitis acceptable include ) another active inflammatory disease An OCT central subfield thickness &lt; 250 micron &gt; 290 micron Presence significant abnormal pattern FAF ocular abnormality fundus photography screening . Uncontrolled intraocular pressure &gt; 22millimetre mercury ( mmHg ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Retinal</keyword>
	<keyword>Ophthalmic</keyword>
	<keyword>Plasmodium . vivax</keyword>
	<keyword>Tafenoquine</keyword>
	<keyword>Pharmacodynamic</keyword>
</DOC>